Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Soleno Therapeutics, Inc. (NASDAQ: SLNO) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Soleno describes itself as a biopharmaceutical company focused on novel therapeutics for rare diseases, and its filings document financial results, material agreements, governance changes, and other significant events related to this business.
Investors can review current reports on Form 8-K in which Soleno announces quarterly and preliminary financial results, operating metrics for VYKAT XR (diazoxide choline) extended-release tablets, and updates on the U.S. launch of this once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. These filings incorporate press releases that discuss product revenue, profitability, cash balances, and other financial information.
Filings also describe capital structure and financing arrangements, including an accelerated share repurchase (ASR) Agreement with Jefferies LLC for up to $100 million of common stock and a first amendment to Soleno’s loan and security agreement with Oxford Finance LLC and other lenders. The 8-Ks outline key terms of these arrangements, such as prepayment of the purchase price, initial share delivery, and changes to loan availability.
Additional 8-Ks cover corporate governance and Board composition, such as the appointment of an independent director with extensive biopharmaceutical finance experience and the associated equity grants under the company’s equity incentive plan. Other filings provide Regulation FD disclosures on topics like investor presentations and safety-related communications, including Soleno’s description of a serious adverse event reported in the FDA’s FAERS database and its assessment of that event.
On this page, AI-powered tools can help summarize lengthy exhibits and press releases attached to Soleno’s filings, highlight key terms in material agreements, and clarify the implications of reported financial metrics, capital transactions, and governance changes for users reviewing SLNO’s regulatory history.
Soleno Therapeutics reported that its Chief Financial Officer, James H. Mackaness, received equity awards on January 21, 2026. He was granted 28,600 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share, bringing his directly held Common Stock to 131,763 shares after the grant. These RSUs are scheduled to vest 100% on December 15, 2027, contingent on his continued service under the company’s 2014 Equity Incentive Plan.
On the same date, he also received an employee stock option for 32,800 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. One forty-eighth of these option shares will vest on February 1, 2026, with additional installments on each monthly anniversary, subject to continued service.
Soleno Therapeutics reported an equity compensation grant to its Chief Development Officer, Joshi Manher. On January 21, 2026, Manher was awarded 4,100 restricted stock units (RSUs) of common stock at a price of $0 per unit, increasing his directly held RSUs tied to common stock to 20,171 following the grant. Each RSU represents the right to receive one share of common stock, and 100% of this new RSU grant is scheduled to vest on December 15, 2027, subject to continued service under the company’s 2014 Equity Incentive Plan.
On the same date, Manher also received an employee stock option covering 4,700 shares of common stock with an exercise price of $43.65 per share. The option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each one-month anniversary thereafter, conditioned on continued service. All reported holdings in this filing are listed as direct ownership.
Soleno Therapeutics senior vice president of clinical development Michael F. Huang reported equity awards in the company’s stock. On January 21, 2026, he received 10,400 shares of Common Stock for no cash consideration, structured as restricted stock units that each convert into one share if service conditions are met. Following this award, he directly beneficially owned 46,405 shares of Common Stock, some of which are RSUs subject to their own vesting terms.
On the same date, he was also granted an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share, expiring on January 21, 2036. One forty‑eighth of the option vests on February 1, 2026 and on each monthly anniversary thereafter, provided he continues as a service provider, while the 10,400 RSUs are scheduled to vest in full on December 15, 2027 under the same continued‑service condition.
Soleno Therapeutics officer Patricia C. Hirano reported new equity awards. On January 21, 2026, she received 10,400 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s equity plan through that date.
On the same day, she was also granted an employee stock option for 11,900 shares of Common Stock at an exercise price of $43.65 per share. One forty-eighth of these option shares start vesting on February 1, 2026 and then monthly thereafter, contingent on continued service, and the option expires on January 21, 2036. After these transactions, she beneficially owned 22,702 shares of Common Stock directly, along with the newly granted option.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 114,200 shares of Common Stock at $0 cost, identified in the footnotes as restricted stock units (RSUs) that each represent a right to one share of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, Bhatnagar was granted an employee stock option covering 131,400 shares of Common Stock at an exercise price of $43.65 per share. The option begins vesting on February 1, 2026, with 1/48th of the shares vesting on that date and on each monthly anniversary thereafter, subject to continued service. After these transactions, he directly held 583,656 shares of Common Stock and 131,400 derivative securities (stock options).
Soleno Therapeutics, Inc. updated compensation for its top executives and adopted a new change in control and severance plan. For 2026, the Board approved higher base salaries and 2025 cash bonuses for the named officers, including a $765,000 salary and $487,740 bonus for CEO Anish Bhatnagar, along with stock options and restricted stock awards for each executive.
The new Key Executive Change in Control and Severance Plan covers all Vice Presidents and above, including the named officers. If an executive is terminated without cause or resigns for good reason outside a change in control period, the CEO can receive 18 months of salary, a 100% target bonus and 18 months of COBRA coverage, with 25% equity vesting acceleration, while other senior executives receive shorter salary and COBRA periods without equity acceleration. If such a termination occurs during the change in control period, the CEO can receive 24 months of salary, a 150% target bonus, 24 months of COBRA coverage and full equity acceleration, with similarly enhanced benefits and full equity vesting for other covered executives.
Soleno Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing certain preliminary financial results and operating metrics for the three months and year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The information is furnished under the results of operations and financial condition disclosure items and is explicitly stated as "furnished" rather than "filed," which limits how it is treated under securities law and in other future SEC filings.
Soleno Therapeutics insider reports routine tax withholding transaction. A senior officer of Soleno Therapeutics Inc. reported an automatic disposition of company stock related to vested restricted stock units on December 15, 2025.
The filing shows that 904 shares of common stock were withheld by the company at a price of $49.95 per share to cover the officer's tax obligations when RSUs vested. After this transaction, the officer beneficially owned 27,239 shares of Soleno Therapeutics common stock. The reported RSUs each represent a contingent right to receive one share of common stock, subject to vesting conditions.
The reporting person serves as SVP Global Clinical Operations and Patient Advocacy, and this filing reflects a standard administrative equity compensation event rather than an open-market trade.
Soleno Therapeutics insider updates equity holdings after RSU vesting
A Soleno Therapeutics officer, the Chief Commercial Officer, reported an automatic share withholding related to restricted stock units. On December 15, 2025, the company withheld 1,922 shares of common stock at $49.95 per share to cover the reporting person's tax obligations when RSUs vested on that date. After this tax withholding, the officer beneficially owned 43,429 shares of common stock, some of which are RSUs, with each RSU representing a contingent right to receive one share subject to its vesting schedule and conditions.
Soleno Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, James Mackaness. On December 15, 2025, 2,013 shares of common stock were disposed of at a price of $49.95 per share. The shares were withheld by the company to cover the officer’s tax obligations arising from the vesting and settlement of restricted stock units (RSUs).
Following this tax withholding transaction, the reporting person beneficially owns 103,163 shares of Soleno Therapeutics common stock. A portion of this balance consists of RSUs, each representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.